Detalhe da pesquisa
1.
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
Mol Ther
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38751112
2.
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.
Blood
; 139(1): 137-142, 2022 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34657156
3.
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.
Leukemia
; 38(1): 168-180, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38049509
4.
Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis.
Oncoimmunology
; 13(1): 2296712, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38170159
5.
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.
J Mol Med (Berl)
; 100(3): 463-470, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34657968
6.
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
Blood Cancer J
; 12(4): 61, 2022 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35418180
7.
Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
Leukemia
; 36(10): 2396-2407, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35999260
8.
T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?
Front Immunol
; 12: 806529, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35069590
9.
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma.
Cancer Cell
; 40(6): 587-589, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35588736
10.
Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
Leukemia
; 36(12): 2950, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36347926